Histogenics was acquired by Ocugen, (Nasdaq: OCGN) on September 27, 2019.
Histogenics (Nasdaq: HSGX) is a leader in personalized restorative cell therapies (RCT) for active living. Our first investigational product candidate, NeoCart® is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA).
Read our community guidelines: https://goo.gl/Qtusgh
Company Details
- Employees
- 10
- Founded
- -
- Address
- Waltham, Ma 02451, Us
- Phone
- (781) 547-4452
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- histogenics.com
- Keywords
- Regenerative Medicine, Tissue Engineering, Musculoskeletal and Orthopaedics, Cartilage Regeneration and Repair.
- HQ
- Waltham, MA
Histogenics Corporation Questions
Histogenics Corporation's helpline number is (781) 547-4452
Histogenics Corporation's website is histogenics.com
Histogenics Corporation's LinkedIn profile is https://www.linkedin.com/company/histogenics
Histogenics Corporation has
10 employees.
View email and phone details for 10
employees at Histogenics Corporation.
Histogenics Corporation's industry is
Biotechnology Research
Histogenics Corporation's top competitors are
Biogen,
Genome International,
Verastem Oncology,
Eyepoint,
Ert,
Ksq Therapeutics, Inc.,
Forebatten Foundation,
Vanguard Clinical, Inc.,
Histogenetics,
Ocugen.
Histogenics Corporation's support email address is investorrelations@histogenics.com
Histogenics Corporation's categories are Biotechnology Research
Histogenics Corporation's founding year is 2000
